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Abstract
Objectives—To assess neurodevelopmental (ND) outcomes among biliary atresia (BA) 
participants with their native liver at ages 12 months (Age 1) and 24 months (Age 2) years, and to 
evaluate variables predictive of ND impairment.
Study design—Participants enrolled in a prospective longitudinal multi-center study underwent 
ND testing with either the Bayley Scales of Infant Development, 2nd edition (BSID-II) or Bayley 
Scales of Infant and Toddler Development, 3rd edition (Bayley-III). Scores (normative 
mean=100±15) were categorized as ≥100, 85-99, and <85 for chi-square analysis. Risk for ND 
impairment (defined as at least one score <85 on BSID-II or Bayley-III scales) was analyzed using 
logistic regression.
Results—148 children completed 217 Bayley examinations (Age 1 n=132; Age 2 n=85). ND 
score distributions significantly shifted downward compared with test norms at Ages 1 and 2. 
Multivariate analysis identified ascites (OR=3.17, P = .01) and low length z-scores at time of 
testing (OR=0.70, p<0.04) as risk factors for Physical/Motor Impairment; low weight z-score 
(OR=0.57, p=0.001) and ascites (OR=2.89, p=0.01) for Mental/Cognitive/Language Impairment at 
Age 1. An unsuccessful hepatoportoenterostomy was predictive of both Physical/Motor (OR=4.88, 
p<0.02) and Mental/Cognitive/Language Impairment (OR=4.76, p=0.02) at Age 2.
Conclusion—Participants with biliary atresia surviving with native livers after HPE are at 
increased risk for ND delays at 12 and 24 months of age. Those with unsuccessful HPE are over 4 
times more likely to have ND impairment compared with those with successful HPE. Growth 
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delays and/or complications indicating advanced liver disease should alert clinicians to risk for ND 
delays, and expedite appropriate interventions.
Trial Registration—Clinicaltrials.gov NCT00061828 and NCT00294684
Keywords
chronic liver disease; Kasai; cognitive; motor
Biliary atresia is the most common cause of chronic progressive liver disease in children, 
manifesting as cholestatic jaundice shortly after birth. It results from an inflammatory and 
fibrosing obstruction of extrahepatic bile ducts and abnormalities of the intrahepatic bile 
ducts 1. The primary treatment is surgical hepatoportoenterostomy (HPE) performed as early 
as possible in an attempt to re-establish biliary flow 2. Despite surgical treatment, most 
patients require liver transplant in childhood 3, but survival with native liver into school age 
4
 and adulthood 5-8 is achievable, and understanding the challenges these patients may 
encounter at the earliest phase possible is key. A recent prospective study of infants with 
biliary atresia demonstrated that failure to achieve a serum total bilirubin level of <2.0 
mg/dL in the first 3 months after HPE is associated with increased risk of various medical 
complications including ascites, coagulopathy, and failure to thrive 9. However, 
neurodevelopmental outcomes were not evaluated. Prior single-center reports describing ND 
functioning in BA infants before LT 5-8 were limited by small samples. ND data from a 
large, contemporaneous, multi-center cohort of young BA patients with native liver followed 
longitudinally can better inform intervention strategies aimed at improving overall outcomes 
for this population.
The Biliary Atresia Research Consortium (BARC) was established in 2002 by the National 
Institutes of Health to improve understanding of the etiology of BA, its natural history, and 
clinical outcomes, and to develop interventional strategies to improve outcomes. BARC was 
expanded into the Childhood Liver Disease Research Network (ChiLDReN) in 2009. In this 
prospective multi-center study, ND outcomes at 1- and 2- years of age were assessed in a 
cohort of BA children alive with native liver followed longitudinally in ChiLDReN. We 
hypothesized that BA patients with their native livers at ages 1 and 2 years would exhibit 
significant ND delays and that specific demographic and clinical variables would be 
predictive of worse ND outcomes.
Methods
Study participants were infants with BA enrolled in the ChiLDReN's Prospective Study of 
Infants and Children with Cholestasis (PROBE) Protocol (Clinicaltrials.gov: NCT00061828) 
between July 1, 2004, and November 1, 2012, who underwent HPE at a ChiLDReN site. 
Informed consent was obtained from parents or guardians and the protocol was carried out 
under IRB approval. A subset of these infants with biliary atresia with birth weight >2 kg 
was co-enrolled in the Steroids in Biliary Atresia Randomized Trial (START), a prospective, 
randomized double-blinded, placebo-controlled trial of corticosteroids as adjunctive therapy 
following HPE for BA (Clinicaltrials.gov: NCT00294684)10. Exclusion criteria for this 
present study included birth weight ≤2000 grams, acute liver failure, previous hepatobiliary 
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surgery (other than HPE), sepsis, hypoxia, shock, malignancy, primary hemolytic disease, 
parenteral nutrition-associated cholestasis, extracorporeal membrane oxygenation (ECMO)-
associated cholestasis, or LT.
Data Collection
Data were prospectively collected and entered into a centralized database. Baseline data 
included patient demographics, medical history (age at HPE, the presence of BA splenic 
malformation syndrome (BASM: asplenia or polysplenia), family history, and laboratory 
studies9. START randomization group (START steroid or START placebo) or PROBE only 
assignment were also recorded. Research visits were scheduled 1, 2, 3, and 6 months after 
HPE, and then at 12, 18, and 24 months of age. Longitudinal data included anthropometry 
measures, liver biochemical values, and interval history of ascites, cholangitis, spontaneous 
bacterial peritonitis, gastrointestinal bleeding, and nasogastric feeding within the preceding 
year. Response to HPE was dichotomized into two groups based upon serum total bilirubin 
levels (TB) in the first 3 months after HPE 9. “Unsuccessful HPE” was defined for those 
patients never achieving a TB < 2.0 mg/dL (34.2 μmol/L) in the first 3 months post-HPE. 
“Successful HPE” was defined for those patients having any TB < 2.0 mg/dL (34.2 uM) 
within the first 3 months post-HPE. ND testing was performed at 1 year and 2 years of age 
(±2 months).
Neurodevelopmental Assessment Measures
The Bayley Scales of Infant Development, second edition (BSID-II) was used to assess ND 
outcomes through January 2010 11. Starting in February 2010, all participants who were new 
to the study completed the updated Bayley Scales of Infant and Toddler Development, third 
edition (Bayley-III) 12. However, participants previously tested with the BSID-II at Age 1, 
were re-tested with the BSID-II version at Age 2 to be consistent. Both versions are normed 
for use between patient ages 1 – 42 months of age, and involve a standard series of 
developmental play tasks which are organized into scales yielding standardized scores (mean 
= 100 ±15). The Bayley-III improved upon the BSID-II with significant changes in test 
structure, updated norms, and improved psychometrics. Participants assessed with the BSID-
II completed the “Mental” and “Physical” scales; those assessed with the Bayley-III 
completed “Cognitive”, “Language”, and “Motor” scales.
Statistical Analyses
We used descriptive statistics to report continuous and categorical ND outcomes, and all 
demographic and other clinical characteristics. One-sample t-test was used to determine 
whether the mean Bayley scores in our sample were lower than the test norms (100 ± 15). 
Domain scores for each Bayley version (BSID-II – Physical/Mental; or Bayley-III – Motor/
Cognitive/Language) were categorized as ≥100 (z-score≥0), 85-99 (z-score between 0 and 
-1), and <85 (z-score < -1). Chi-square test was used to compare the distribution of Bayley 
scores in the study cohort in these 3 bins to the normal population. P values ≤ 0.05 were 
considered statistically significant.
Because of the significant changes to the construction and content of the scales, BSID-II and 
Bayley-III scores are only modestly correlated and are not equivalent. We combined results 
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from the two Bayley versions to derive ND outcomes reflecting the entire sample for 
modeling. The two primary ND outcomes were “At Risk for Physical/Motor Delay”, defined 
as either a BSID-II Physical score <85 or Bayley-III Motor score <85, and “At Risk for 
Mental/Cognitive/Language Delay”, defined as BSID-II Mental score <85 or Bayley-III 
Cognitive and/or Language score <85. This approach resulted in characterization of below 
average scores on either Bayley version as “at risk” (capturing those performing relatively 
worse regardless of measure).
Bowker test of symmetry was used to assess agreement between the three categorical 
responses for each domain between Age 1 and Age 2. Associations between patient 
characteristics and the two ND outcomes were determined using logistic regression models. 
In univariate analyses, risk factors were included one at a time. In multivariate analysis, we 
first included all risk factors of interest and a backward stepwise selection procedure was 
used. A p-value <0.1 was used as both inclusion and exclusion criteria in the stepwise 
selection procedure. Acknowledging the widely reported systematic differences between 
BSID-II and Bayley-III scores, Bayley version was adjusted in both univariate and 
multivariate models 13. Due to missing data, multiple imputations were used for multivariate 
analysis using IVEware 14. All other analyses were performed using SAS.
Results
A total of 373 PROBE participants with BA were identified. Participants who underwent LT 
(n=86), died (n=15), were withdrawn prior to 1 year of age (n=12), or were <2 kg at birth 
(n=8) did not undergo ND assessment (Figure 1; available at www.jpeds.com); 132 (52%) of 
remaining 252 eligible participants completed ND testing at Age 1, and 85 (43%) of 196 
eligible had ND testing at Age 2. Eligible participants with ND testing at Age 1 (N=132) 
were more likely than those who were eligible but not tested (N=120) to be white, non-
Hispanic, have college-educated parents, and have a successful HPE (p<0.04). Similarly, 
Age 2 tested participants (n=85) were more likely than those who were eligible but not 
tested (n=111) to be white and have college-educated parents (p<0.04) [data not shown]. 
Figure 1 provides details of sample ascertainment. A total of 217 completed Bayley 
assessments from 148 participants were available for the final analysis.
Table I provides demographic, clinical and medical characteristics for Age 1 and Age 2 
participants. Participants at Age 1 had more medical events in the preceding year than Age 2 
participants, including ascites (29% vs 14%) and cholangitis (51% vs. 18%). At Age 1, 
among 150 participants with successful HPE who were eligible for ND testing, 91 (61%) 
completed ND testing, compared with 29 (37%) of 78 with unsuccessful HPE (p=0.0006). 
This was seen again at Age 2, with 67 (50%) of 133 eligible participants with successful 
HPE completed testing, whereas only 10 (26%) of 39 eligible participants with unsuccessful 
HPE completed testing.
Bayley Scores in Age 1 and Age 2 participants
Participants completing the 2 Bayley versions did not differ significantly in terms of sex, 
race, ethnicity, and/or highest household education. Table 2 (available at www.jpeds.com) 
provides mean Bayley scores by measure, scale, and age. At Age 1, mean participant scores 
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on all BSID-II and all but one Bayley-III scale (Cognitive) were significantly lower than test 
norms with medium to large effect sizes (0.50 to 1.15). The Bayley-III Cognitive scale mean 
trended towards significance (effect size 0.21). At age 2, mean scores for those tested with 
BSID-II continued to show robust differences from test norms (medium effect sizes 
0.65-0.72). Those tested with Bayley-III showed more modest differences from test norms 
on Cognitive and Motor scales (small effect sizes 0.30-0.43), and no significant difference 
on the Language scale.
As seen in Figure 2, the distribution of scores at Age 1 was shifted downward, with a higher 
proportion of below-average scores than expected compared with the normal population, for 
all BSID-II and Bayley-III scales except Cognitive (p<0.05). At Age 1, participants' scores 
fell below 85 at least twice the expected rate on BSID-II Physical and Bayley-III Motor 
(59% and 32% vs. 16% expected), and BSID-II Mental and Bayley-III Language scales 
(38% and 33% vs. 16% expected). At Age 2, scores were still shifted downward for those 
completing the BSID-II, but differences from the expected normal distribution were not 
significant on Bayley-III.
Sixty-nine participants completed ND testing (45 BSID-II and 21 Bayley-III) at both Age 1 
and Age 2, and used the same Bayley version each time. The distribution of motor and 
cognitive subdomain scores did not change significantly over time in these subjects.
Predictors for being “At Risk for Physical/Motor Delay”
Results of univariate and multivariate analyses identifying “At risk for Physical/Motor 
Delay” predictors are reported in Table 3. Univariate analysis identified older age at HPE, 
the presence of one or more medical complications (ascites or GI bleed in prior year or 
thrombocytopenia at testing), ascites alone in the prior year, and decreased length z-scores at 
time of testing as risk factors for Physical/Motor impairment at 1 year of age. Unsuccessful 
HPE was also identified a risk factor for Physical/Motor delay at 1 and 2 years of age. In 
multivariate analysis, only ascites (OR 3.17) and lower length z-score (OR 0.70) were 
independently associated with higher risk of physical/motor impairment in participants at 
one year of age, and unsuccessful HPE remained the unique predictor of higher risk at Age 2 
(OR 4.88).
Predictors for being “At Risk for Mental, Cognitive or Language Delay”
Univariate and multivariate analyses of risk factors associated with Mental/Cognitive/
Language delay are provided in Table 4. At Age 1, univariate analysis identified five 
significant predictors of Mental/Cognitive/Language delays: low weight and length z-scores, 
higher recent serum total bilirubin level, ascites, and older age at HPE. Only race, low 
weight at time of ND testing (OR 0.57) and ascites within the prior year (OR 2.89) retained 
significance by multivariate analysis. Univariate analysis of participants at Age 2 revealed 
higher level of serum total bilirubin at testing, older age at HPE, unsuccessful HPE, and 
presence of medical complications as risk factors for impairments in Mental/Cognitive/
Language development; whereas household education of college or greater was protective. 
On multivariate analysis, only two variables retained significance: unsuccessful HPE (OR 
4.76) and household educational level (OR 0.26).
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Successful vs Unsuccessful HPE and “At risk for ND delay” Outcomes
At Age 1, 53% (46/87) of participants with successful HPE were identified as being at risk 
for Physical/Motor delay compared with 77% (20/26) of participants with unsuccessful 
HPE. At Age 2, 25% (16/64) of participants with successful HPE were identified as at risk in 
this domain, compared with 66% (6/9) of patients with unsuccessful HPE; 38% (33/88) of 
Age 1 and 33% (22/66) of Age 2 participants with successful HPE were at risk for Mental/
Cognitive/Language delay, compared with 55% (16/29) Age 1 participants and 67% (6/9) 
Age 2 participants with unsuccessful HPE.
Discussion
In this multicenter study, we demonstrate that young children with BA surviving with native 
livers after HPE are at increased risk for ND delays at 1 and 2 years of age compared with 
test norms. Markers of advanced liver disease such as ascites and growth deficits were 
associated with worse ND outcomes. ND scores remained stable across categories (≥100, 
85-99, <85) from Age 1 to 2 in those tested at both times. Children with BA living with an 
unsuccessful HPE have a 2 to 5 times higher incidence of delays in both Physical/Motor 
skills as well as Mental/Cognitive/Language development during the first 2 years of life.
Recent research initiatives have focused largely on neurocognitive outcomes in cohorts of 
pediatric LT recipients, comprised largely of BA participants and show that developmental 
delays are prominent at the time of listing and post-transplant 15, 16. Only a handful of small, 
single-center studies have examined ND outcomes specifically in infants with BA and their 
native livers, with cognitive and motor delays most consistently reported in both pre-
transplant 5, 6, 8, 17 as well as one-year post-LT patient populations 17.
In our study, unsuccessful HPE was associated with greatly increased risk of ND delays with 
75% at risk in the Physical/Motor domain, and 50% at risk for Mental/Cognitive/Language 
delays at Age 1. Nevertheless, even BA patients with evidence of a successful HPE remain 
vulnerable, with 1/4 at risk for Physical/Motor delays, and 1/3 at risk for Mental/Cognitive/
Language delays at 2 years of age. Given that the median age at LT is less than 2 years, our 
results underscore the importance of identifying and addressing those at risk for ND delays 
swiftly even when they do not meet indications for LT. Previous detailed characterization of 
children with biliary atresia with their native liver 5 or more years after HPE (ie, who are not 
listed for LT) revealed progressive clinical or biochemical evidence of chronic liver disease 
and its consequences 18. Strategies are needed to identify those most at risk for ND delays 
and enable interventions at the earliest age possible to ensure optimal outcomes for patients 
with this chronic childhood liver condition.
Infancy and early childhood is a time of critical brain development, and an important period 
for ND surveillance, especially in children with chronic illnesses. Infants diagnosed with BA 
are potentially more vulnerable given the absence of alternate treatments and the need for 
timely surgical intervention (HPE) requiring prolonged general anesthesia (GA) within the 
first months of life. However, a recent study examining 336 infants found few significant 
effects of GA in the first year of life on ND outcomes compared with controls 19. 
Additionally, interim results from two long-term studies – one a randomized trial comparing 
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GA with regional anesthesia20, and another looking at sibling pairs21 – noted no significant 
effect of GA on ND outcomes using standardized testing after a single GA exposure. Given 
the essential role of GA in order for surgical procedures (like the HPE) to be performed 
safely in infants, concern for GA on the developing brain should not result in a delay in the 
timely completion of the HPE procedure, as it is likely that the ND issues are related to the 
primary conditions and comorbidities, and not to the use of GA20, 21.
Our study found that BA children with ascites at 1 year of age were 3 times more likely to 
have Physical/Motor delays. The presence of ascites, a known marker of advanced liver 
disease, may impair motor development due to abdominal distension that could potentially 
inhibit normal infant movement and exploration 6, 7, 17, 22. Advanced liver disease may also 
affect motor development through its effect on the brain and its association with poor 
nutritional status and loss of muscle mass. Other markers of advanced liver disease, such as 
international normalized ratio (INR), have also been reported to correlate negatively with 
both gross and fine motor performance 6, although, this was not found in our cohort. Motor 
deficits have been found to persist through school age in patients with chronic liver disease 
23
. An association has been found between motor deficits and long-term outcomes in 
pediatric acute liver failure 24, and in children with extrahepatic portal vein obstruction with 
signs of hyperammonemia and cerebral edema on imaging 25, 26. Ascites was also a 
significant predictor of Mental/Cognitive/Language attainment at 1 and 2 years of age. 
Diseased liver with a reduced capacity to metabolize a variety of potentially cerebrotoxic 
substances in the blood may also be contributing to cognitive deficits in infants with 
advanced liver disease and portal hypertension7.
Failure to thrive is a serious consequence of chronic liver disease and is associated with 
increased morbidity and mortality 27. Our study found that lower weight and length z-scores 
at testing were significant predictors of Mental/Cognitive/Language delay at 1 year of age 
and lower length z-scores predicted risk for Physical/Motor delay at 1 year, but neither 
length nor weight predicted outcome at 2 years of age. In our cohort, participants surviving 
to age 2 with their native livers had mean length and weight z-scores much closer to the 
average than participants tested at Age 1, who underwent LT or died prior to Age 2 testing. 
Unfortunately, growth delays related to early malnutrition have consistently predicted long-
term neurocognitive outcomes in chronic liver disease patients, well after LT27, suggesting 
an early possibly irreversible impact on brain development. These findings suggest that 
optimizing early nutrition and growth in infants with BA could potentially have important 
ramifications for ND outcomes.
In our study, a small sub-sample was simultaneously enrolled in a blinded, randomized, 
placebo-controlled study of corticosteroids as adjunctive therapy post-HPE 28. Steroid use 
was not associated with ND outcomes in these patients. The limited research available on 
cognitive effects of corticosteroids in children suggests potential acute worsening in areas 
such as attention, memory, and executive functioning 29, 30 that are not measurable in 
infants. Thus, prospective assessment of relevant functional domains later in development is 
needed before concluding that corticosteroids have no impact on ND outcomes in BA 
patients.
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Despite examining ND outcomes in the largest prospective cohort of infants with biliary 
atresia to date, we acknowledge potential limitations and biases of this study. First, our 
sample reflects at best 50% attainment of eligible participants. Although specific reasons for 
non-participation were not available, ND data collection in infants (particularly those with a 
serious chronic disease or those who are extremely ill) is challenging. Secondly, a much 
larger proportion of participants with successful HPE underwent ND testing at both time 
points compared with eligible participants with unsuccessful HPE, indicating that our 
sample was likely healthier than the general BA population. Indeed, our study did not 
capture children with unsuccessful HPE who were transplanted (or died) prior to Age 1, and 
participants with ND testing at Age 2 were healthier than those with testing at Age 1 for the 
same reason (drop-out due to death or LT after Age 1). This bias towards recruitment of 
healthier participants is common in research studies, and actually, underscores the 
significance of these findings. Finally, a particular challenge to the interpretation of this 
database was the mid-study shift in Bayley version. The test structure changed significantly 
with major revision and redistribution of items from 2 core scales on the BSID-II to 3 on the 
Bayley-III, thereby eliminating the possibility of simply combining scores across versions 
for analysis. Validity studies show only modest correlations between the two versions, with 
significantly lower scores on BSID-II compared with Bayley-III editions 12, 13. Indeed, this 
pattern held in our own sample. Other studies have also faced this challenge, and used 
various strategies to attempt to equate the two versions by conversion algorithm, regression 
analysis, or setting a higher cut point on Bayley-III Cognitive (and Language) scales 
compared with BSID-II Mental scale 31-34. Although these strategies have all assumed that 
the Bayley-III underestimates ND delay, there is now accumulating evidence that BSID-II 
overestimates ND delay, and Bayley-III scores are actually more valid 11. Some studies are 
reporting high correlations of 0.81 and 0.78 between Bayley-III Cognitive and Language 
scores at 2 years of age with Wechsler Preschool and Primary Scale of Intelligence-III 
(WPPSI-III) Full Scale IQ at 4 years of age in preterm children, with 81% of studied 
participants maintaining the same developmental classification from Bayley-III to WPPSI-
III 35, 36. In our study, we addressed this dilemma with the definition of “at risk” groups for 
modeling, which allowed capture of all patients with scores at the lower end of the 
distribution regardless of version or scale. We also ensured that our univariate multivariate 
analyses adjusted for Bayley version. Only longitudinal assessment of this BA population 
will determine if the risk for ND delays found within the first 2 years will persist at older 
ages; these studies are in progress to document development and evaluate the impact of 
interventions.
In conclusion, this study provides benchmarks for ND outcomes expected in 1- and 2-year-
old children with BA with their native livers. These young children remain at significant risk 
for ND impairments including both Physical/Motor and Mental/Cognitive/Language 
domains even in those patients with a successful HPE and not listed for pediatric LT. Stunted 
growth and complications indicative of advanced liver disease are associated with worse ND 
outcomes. These findings suggest that strategies to promote successful HPE surgery (such as 
earlier diagnosis and intervention) and optimize growth and nutrition may improve ND 
outcomes in this vulnerable population.
Ng et al. Page 9
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Acknowledgments
Financial Support: Supported by U01 grants from the National Institute of Diabetes and Digestive and Kidney 
Diseases (DK 62445 [Mount Sinai School of Medicine], DK 62497 [Cincinnati Children's Hospital Medical 
Center], DK 62470 [Children's Healthcare of Atlanta], DK 62481 [The Children's Hospital of Philadelphia], DK 
62456 [The University of Michigan], DK 84536 [Riley Hospital for Children], DK 84575 [Seattle Children's 
Hospital], DK 62500 [UCSF Children's Hospital], DK 62503 [Johns Hopkins School of Medicine], DK 62466 
[Children's Hospital of Pittsburgh of UPMC], DK 62453 [Children's Hospital Colorado], DK 62452 [Washington 
University School of Medicine], DK 84538 [Children's Hospital Los Angeles], DK 62436 [Ann & Robert H Lurie 
Children's Hospital of Chicago], DK103149 [Texas Children's Hospital], DK103135 [The Hospital for Sick 
Children], DK103140 [University of Utah]), and by CTSA grants from the National Center for Advancing 
Translational Sciences: UL1TR000003 [The Children's Hospital of Philadelphia, Philadelphia, PA], UL1TR000077 
[Cincinnati Children's Hospital Medical Center, Cincinnati, OH], UL1TR000130 [Children's Hospital Los Angeles, 
Keck School of Medicine University of Southern California, Los Angeles, CA], UL1TR000067 [Mount Sinai 
School of Medicine, New York, NY], U01DK062500 and UL1TR000004 [UCSF Benioff Children's Hospital, 
University of California, San Francisco, CA], UL 1TR000424 [Johns Hopkins School of Medicine, Baltimore, 
MD], UL1TR000005 [Children's Hospital Pittsburgh of UPMC, Pittsburgh, PA], UL1TR000448 [Washington 
University, St. Louis, MO], UL1TR000150 [Ann and Robert H. Lurie Children's Hospital and Northwestern 
University, Chicago, IL], and T32DK67009, UL1TR001082 [University of Colorado School of Medicine, 
Children's Hospital Colorado, Aurora, CO]. E.A. holds stock in ≪ ≫. K.M. holds stock in ≪ ≫ and received 
research support from ≪ ≫. B.H. holds stock in ≪ ≫ and is employed by Merck. V.N. is a consultant for ≪ ≫. 
B.S. is a consultant for ≪ ≫. P.R. is a consultant for ≪ ≫, is on the speaker's bureau of ≪ ≫, and receives research 
support from ≪ ≫. K.S. is a consultant for ≪ ≫, and receives research support from ≪ ≫. R.S. is a consultant for 
≪ ≫ and receives research support from ≪ ≫. S.K. is a consultant for ≪ ≫. J.M. serves on the advisory board for 
≪ ≫ and receives research support from ≪ ≫. J.B. receives research support from ≪ ≫.
Appendix
Additional members of the Childhood Liver Disease Research Network (ChiLDReN)
Houston
Dr. Paula M. Hertel, MD, Baylor College of Medicine, Co-Investigator, Texas Children's 
Hospital, Houston, TX.
Dr. Sanjiv Harpavat, MD, PhD, Baylor College of Medicine, Co-Investigator, Texas 
Children's Hospital, Houston, TX.
Dr. Mary L. Brandt, MD, FACS, Baylor College of Medicine, Co-Investigator, Texas 
Children's Hospital, Houston, TX.
Dr. Daniel H. Leung, MD, Baylor College of Medicine, Co-Investigator, Texas Children's 
Hospital, Houston, TX.
Baltimore
Dr. Wikrom Karnsakul, MD, Johns Hopkins School of Medicine, Co-investigator, Baltimore, 
MD.
Bethesda
Rebecca Torrance, RN, Liver Diseases Research Branch, National Institute of Diabetes and 
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
Ng et al. Page 10
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sherry Hall, MS, Liver Diseases Research Branch, National Institute of Diabetes and 
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
Dr. Edward Doo, MD, Liver Diseases Research Branch, National Institute of Diabetes and 
Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
Dr. Jay H. Hoofnagle, MD, Liver Diseases Research Branch, National Institute of Diabetes 
and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD
Chicago
Dr. Peter Whitington, MD, Ann and Robert H. Lurie Children's Hospital of Chicago, 
Principal Investigator, Pediatrics Division of Gastroenterology, Hepatology, and Nutrition, 
Chicago, IL.
Dr. Lee Bass, MD, Ann & Robert H. Lurie Children's Hospital, Co-Investigator, Division 
ofPediatric Gastroenterology, Hepatology and Nutrition Chicago, IL
Cincinnati
Dr. Alexander G. Miethke, MD, Cincinnati Children's Hospital, Co-Investigator, Division of 
Pediatric Gastroenterology, Hepatology and Nutrition, Cincinnati, OH.
Dr. James E. Heubi, MD, Cincinnati Children's Hospital, Co-Director, Bile Acid Core, 
Gastroenterology, Hepatology and Nutrition, Cincinnati, OH.
Dr. Kenneth Setchell, PhD, Cincinnati Children's Hospital, Co-Director, Bile Acid Core, 
Department of Pediatrics – Pathology, Cincinnati, OH.
Dr. Kevin E. Bove, MD, Cincinnati Children's Hospital, Co-Investigator, Pathology, Division 
of Pediatric Pathology and Laboratory Medicine, Cincinnati, OH.
Dr. Greg Tiao, MD, Cincinnati Children's Hospital, Co-Investigator, Surgeon Division of 
Pediatric and Thoracic Surgery, Cincinnati, OH.
Colorado
Dr. Cara L. Mack, MD, Children's Hospital Colorado, Multiple Principle Investigator, 
Section of Pediatric Gastroenterology, Hepatology, Nutrition, Aurora, CO.
Dr. Michael R. Narkewicz, MD, Children's Hospital Colorado, Co-Investigator, Section of 
Pediatric Gastroenterology, Hepatology, Nutrition, Aurora, CO.
Dr. Amy G. Feldman, MD, Children's Hospital Colorado, Co-Investigator, Section of 
Pediatric Gastroenterology, Hepatology, Nutrition, Aurora, CO.
Dr. Shikha S. Sundaram, MD, Children's Hospital Colorado, Co-Investigator, Section of 
Pediatric Gastroenterology, Hepatology, Nutrition, Aurora, CO.
Ng et al. Page 11
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr. Frederick J. Suchy, MD, Children's Hospital Colorado, Co-Investigator, Director, 
Children's Hospital Research Institute, Aurora, CO.
Dr. Frederick M. Karrer, MD, Children's Hospital Colorado, Co-Investigator, Pediatric 
Surgery, Aurora, CO.
Dr. Mark Lovell, MD, Children's Hospital Colorado, Co-Investigator, Pediatric Pathology, 
Clinical Genetics, Aurora, CO.
Dr. Johan L. Van Hove, MD, Children's Hospital Colorado, Co-Investigator, Clinical 
Genetics, Aurora, CO.
Philadelphia
Dr. Elizabeth B. Rand, MD, Children's Hospital of Philadelphia, Co-Investigator, 
Philadelphia, PA.
Pittsburgh
Dr. James E. Squires, MD, Children's Hospital of Pittsburgh of UPMC, Co-Investigator, 
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Pittsburgh PA.
Dr. Veena L. Venkat, MD, Children's Hospital of Pittsburgh of UPMC, Co- Investigator, 
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Pittsburgh PA.
Dr. Rakesh Sindhi, MD, Children's Hospital of Pittsburgh of UPMC, Co- Investigator, 
Hillman Center for Pediatric Transplantation, Pittsburgh PA.
Dr. Sarangarajan Ranganathan, MD, Children's Hospital of Pittsburgh of UPMC, Co-
Investigator, Department of Pathology, Pittsburgh, PA.
San Francisco
Dr. Laura Bull, PhD, UCSF Benioff Children's Hospital, Genetics Core Lab, UCSF Institute 
for Human Genetics, San Francisco, CA
St. Louis
Dr. Jeffrey Teckman, MD, Saint Louis University School of Medicine, Principal Investigator, 
Saint Louis University/Cardinal, Glennon Children's Medical Center, St. Louis, MO.
Indianapolis
Dr. Molly Bozic, MD, Riley Hospital for Children, Co-Investigator, Pediatric 
Gastroenterology, Indianapolis, IN.
Dr. Girish Subbarao, MD, Riley Hospital for Children, Co-Investigator, Pediatric 
Gastroenterology, Hepatology and Nutrition, Indianapolis, IN.
Ng et al. Page 12
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Seattle
Dr. Simon Horslen, MD, Seattle Children's Hospital, Co-Investigator, Division of 
Gastroenterology and Hepatology, Seattle, WA.
Dr. Evelyn Hsu, MD, Seattle Children's Hospital, Co-Investigator, Division of 
Gastroenterology and Hepatology, Seattle, WA.
Dr. Laura Finn, MD, Seattle Children's Hospital, Co-Investigator, Division of 
Gastroenterology and Hepatology, Seattle, WA.
Dr. Patrick Healey, MD, Seattle Children's Hospital, Co-Investigator, Division of 
Gastroenterology and Hepatology, Seattle, WA.
Los Angeles
Dr. Rohit Kohli, MD, Children's Hospital Los Angeles, Co-Investigator, Division of 
Gastroenterology, Hepatology, and Nutrition, Los Angeles, CA.
Dr. Danny Thomas, MD, Children's Hospital Los Angeles, Co-Investigator, Division of 
Gastroenterology, Hepatology, and Nutrition, Los Angeles, CA.
Dr. Nisreen Soufi, MD, Children's Hospital Los Angeles, Co-Investigator, Division of 
Gastroenterology, Hepatology, and Nutrition, Los Angeles, CA.
Dr. Sonia Michail, MD, FAAP, CPE, AGAF, Children's Hospital Los Angeles, Co-
Investigator, Division of Gastroenterology, Hepatology, and Nutrition, Los Angeles, CA.
Atlanta
Dr. Matt Clifton, MD, Emory University School of Medicine, Co-Investigator, Atlanta, GA.
Dr. Nitika Gupta, MD, Emory University School of Medicine/Children's Healthcare of 
Atlanta, Co-Investigator, Atlanta, GA.
Dr. Rene Romero, MD, Emory University School of Medicine/Children's Healthcare of 
Atlanta, Co-Investigator, Atlanta, GA.
Dr. Miriam Vos, MD, Emory University School of Medicine/Children's Healthcare of 
Atlanta, Co-Investigator, Atlanta, GA.
Dr. Shelley Caltharp, MD, Children's Healthcare of Atlanta, Co-Investigator, Atlanta, GA.
Toronto
Dr. Binita M. Kamath, MD, MBBChir, MRCP, the Hospital for Sick Children, Principal 
Investigator, Division of Pediatric Gastroenterology, Hepatology and Nutrition, Toronto, 
ON.
Ng et al. Page 13
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Dr. Simon C. Ling, MB, ChB, MRCP(UK), the Hospital for Sick Children, Co-Investigator, 
Division of Pediatric Gastroenterology, Hepatology and Nutrition, Toronto, ON.
Dr. Anna Gold, PhD, the Hospital for Sick Children, Co-Investigator, Division of 
Psychology, Toronto, ON.
Dr. Annie Fecteau, MD CM MSc, FRCS(C), FACS, the Hospital for Sick Children, Co-
Investigator, Division of Surgery, Toronto, ON.
Utah
Dr. Stephen L. Guthery, MD, University of Utah, Principal Investigator, Division of 
Pediatric Gastroenterology, Hepatology and Nutrition, Salt Lake City, UT.
Dr. Kyle Jensen, MD, University of Utah, Co- Investigator, Division of Pediatric 
Gastroenterology, Hepatology and Nutrition, Salt Lake City, UT.
Dr. Rebecka Meyers, MD, University of Utah, Co-Investigator, Division of Pediatric 
Surgery, Salt Lake City, UT.
Dr. Amy Lowichik, MD, PhD, University of Utah, Co-Investigator, Division of Pediatric 
Pathology, Salt Lake City, UT.
Dr. Linda Book, MD, University of Utah, Co-Investigator, Division of Pediatric 
Gastroenterology Hepatology and Nutrition, Salt Lake City, UT.
Ann Arbor (Data Coordinating Center)
Dr. Robert M. Merion, MD, University of Michigan, Principal Investigator, Department of 
Transplantation, Ann Arbor, USA
Dr. Cathie Spino, Sc.D., University of Michigan, Co-Investigator, Department of 
Biostatistics, Ann Arbor, MI, USA
Karen Jones, MS, Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
References
1. Hartley JL, Davenport M, Kelly DA. Biliary Atresia. Lancet. 2009; 374:1704–13. [PubMed: 
19914515] 
2. Kasai MSS. A new operation for non-correctable biliary atresia-hepatic portoenterostomy. Shujitsu. 
1959; 13:733–9.
3. Squires RH, Ng V, Romero R, Ekong U, Hardikar W, Emre S, et al. Evaluation of the pediatric 
patient for liver transplantation: 2014 practice guideline by the American Association for the Study 
of Liver Diseases, American Society of Transplantation and the North American Society for 
Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2014; 59:112–
31. [PubMed: 25222807] 
4. Erlichman J, Hohlweg K, Haber BA. Biliary atresia: how medical complications and therapies 
impact outcome. Expert Rev Gastroenterol Hepatol. 2009; 3:425–34. [PubMed: 19673629] 
Ng et al. Page 14
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
5. Caudle SE, Katzenstein JM, Karpen S, McLin V. Developmental assessment of infants with biliary 
atresia: differences between boys and girls. J Pediatr Gastroenterol Nutr. 2012; 55:384–9. [PubMed: 
22516863] 
6. Caudle SE, Katzenstein JM, Karpen SJ, McLin VA. Language and motor skills are impaired in 
infants with biliary atresia before transplantation. J Pediatr. 2010; 156:936–40. , 40.e1. [PubMed: 
20223479] 
7. Stewart SM, Campbell RA, McCallon D, Waller DA, Andrews WS. Cognitive patterns in school-age 
children with end-stage liver disease. J Dev Behav Pediatr. 1992; 13:331–8. [PubMed: 1401116] 
8. Stewart SM, Uauy R, Waller DA, Kennard BD, Andrews WS. Mental and motor development 
correlates in patients with end-stage biliary atresia awaiting liver transplantation. Pediatrics. 1987; 
79:882–8. [PubMed: 2438636] 
9. Shneider BL, Magee JC, Karpen SJ, Rand EB, Narkewicz MR, Bass LM, et al. Total Serum 
Bilirubin within 3 Months of Hepatoportoenterostomy Predicts Short-Term Outcomes in Biliary 
Atresia. J Pediatr. 2016; 170:211–7.e2. [PubMed: 26725209] 
10. Bezerra JA, Spino C, Magee JC, Shneider BL, Rosenthal P, Wang KS, et al. Use of corticosteroids 
after hepatoportoenterostomy for bile drainage in infants with biliary atresia: the START 
randomized clinical trial. Jama. 2014; 311:1750–9. [PubMed: 24794368] 
11. Bayley, N. Bayley Scales of Infant Development, Second Edition: Manual. San Antonio, Texas: 
The Psychological Corporation; 1993. 
12. Bayley, N. Bayley scales of infant development—Third edition. Third. San Antonio, Texas, USA: 
PsychCorp; 2006. 
13. Bayley–III Technical Report 2: Factors Contributing to Differences Between Bayley–III and 
BSID–II Scores. Pearson Education Inc. or its affiliate(s); 2007. 
14. Raghunathan TE, Lepkowski J, Van Hoewyk J, Solenberger. Survey Methodology. A Multivariate 
Technique for Multiply Imputing Missing Values Using a Sequence of Regression Models. 2001
15. Sorensen LG, Neighbors K, Martz K, Zelko F, Bucuvalas JC, Alonso EM. Cognitive and academic 
outcomes after pediatric liver transplantation: Functional Outcomes Group (FOG) results. Am J 
Transplant. 2011; 11:303–11. [PubMed: 21272236] 
16. Reed-Knight B, Lee JL, Cousins LA, Mee LL. Intellectual and academic performance in children 
undergoing solid organ pretransplant evaluation. Pediatr Transplant. 2015; 19:229–34. [PubMed: 
25389073] 
17. Wayman KI, Cox KL, Esquivel CO. Neurodevelopmental outcome of young children with 
extrahepatic biliary atresia 1 year after liver transplantation. J Pediatr. 1997; 131:894–8. [PubMed: 
9427896] 
18. Hadzic N, Davenport M, Tizzard S, Singer J, Howard ER, Mieli-Vergani G. Long-term survival 
following Kasai portoenterostomy: is chronic liver disease inevitable? J Pediatr Gastroenterol Nutr. 
2003; 37:430–3. [PubMed: 14508212] 
19. Nestor KA, Zeidan M, Boncore E, Richardson A, Alex G, Weiss M, et al. Neurodevelopmental 
outcomes in infants undergoing general anesthesia. J Pediatr Surg. 2017; 52:895–900. [PubMed: 
28342581] 
20. Davidson AJ, Disma N, de Graaff JC, Withington DE, Dorris L, Bell G, et al. Neurodevelopmental 
outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy 
(GAS): an international multicentre, randomised controlled trial. Lancet. 2016; 387:239–50. 
[PubMed: 26507180] 
21. Sun LS, Li G, Miller TL, Salorio C, Byrne MW, Bellinger DC, et al. Association Between a Single 
General Anesthesia Exposure Before Age 36 Months and Neurocognitive Outcomes in Later 
Childhood. Jama. 2016; 315:2312–20. [PubMed: 27272582] 
22. Stewart SM, Uauy R, Waller DA, Kennard BD, Benser M, Andrews WS. Mental and motor 
development, social competence, and growth one year after successful pediatric liver 
transplantation. J Pediatr. 1989; 114:574–81. [PubMed: 2647947] 
23. Almaas R, Jensen U, Loennecken MC, Tveter AT, Sanengen T, Scholz T, et al. Impaired motor 
competence in children with transplanted liver. J Pediatr Gastroenterol Nutr. 2015; 60:723–8. 
[PubMed: 25658058] 
Ng et al. Page 15
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
24. Sorensen LG, Neighbors K, Zhang S, Limbers CA, Varni JW, Ng VL, et al. Neuropsychological 
functioning and health-related quality of life: pediatric acute liver failure study group results. J 
Pediatr Gastroenterol Nutr. 2015; 60:75–83. [PubMed: 25250681] 
25. Yadav SK, Saksena S, Srivastava A, Srivastava A, Saraswat VA, Thomas MA, et al. Brain MR 
imaging and 1H-MR spectroscopy changes in patients with extrahepatic portal vein obstruction 
from early childhood to adulthood. AJNR American journal of neuroradiology. 2010; 31:1337–42. 
[PubMed: 20223885] 
26. Yadav SK, Srivastava A, Srivastava A, Thomas MA, Agarwal J, Pandey CM, et al. Encephalopathy 
assessment in children with extra-hepatic portal vein obstruction with MR, psychometry and 
critical flicker frequency. J Hepatol. 2010; 52:348–54. [PubMed: 20137823] 
27. Rodriguez-Baez N, Wayman Karen I, Cox Kenneth L. Cox Growth and Development in Chronic 
Liver Disease. NeoReviews. 2011; 2
28. Venkat VL, Shneider BL, Magee JC, Turmelle Y, Arnon R, Bezerra JA, et al. Total serum bilirubin 
predicts fat-soluble vitamin deficiency better than serum bile acids in infants with biliary atresia. 
Journal of pediatric gastroenterology and nutrition. 2014; 59:702–7. [PubMed: 25419594] 
29. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more 
variable than expected in children. The Journal of rheumatology. 1998; 25:1995–2002. [PubMed: 
9779857] 
30. Mrakotsky C, Forbes PW, Bernstein JH, Grand RJ, Bousvaros A, Szigethy E, et al. Acute cognitive 
and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel 
disease. Journal of the International Neuropsychological Society : JINS. 2013; 19:96–109. 
[PubMed: 23157730] 
31. Moore T, Johnson S, Haider S, Hennessy E, Marlow N. Relationship between test scores using the 
second and third editions of the Bayley Scales in extremely preterm children. J Pediatr. 2012; 
160:553–8. [PubMed: 22048046] 
32. Jary S, Whitelaw A, Walloe L, Thoresen M. Comparison of Bayley-2 and Bayley-3 scores at 18 
months in term infants following neonatal encephalopathy and therapeutic hypothermia. Dev Med 
Child Neurol. 2013; 55:1053–9. [PubMed: 23927586] 
33. Younge N, Goldstein RF, Bann CM, Hintz SR, Patel RM, Smith PB, et al. Survival and 
Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med. 2017; 376:617–28. 
[PubMed: 28199816] 
34. Johnson S, Moore T, Marlow N. Using the Bayley-III to assess neurodevelopmental delay: which 
cutoff should be used? Pediatric research. 2014; 75:670–4. [PubMed: 24492622] 
35. Aylward GP. Continuing issues with the Bayley-III: where to go from here. J Dev Behav Pediatr. 
2013; 34:697–701. [PubMed: 24217027] 
36. Bode MM, D'Eugenio DB, Mettelman BB, Gross SJ. Predictive validity of the Bayley, Third 
Edition at 2 years for intelligence quotient at 4 years in preterm infants. J Dev Behav Pediatr. 
2014; 35:570–5. [PubMed: 25370298] 
List of Abbreviations
BARC Biliary Atresia Research Consortium
Bayley-III Bayley Scales of Infant and Toddler Development, 3rd 
edition
BSID-II Bayley Scales of Infant Development, 2nd edition
ChiLDReN Childhood Liver Diseases Research Network
HPE Hepatoportoenterostomy
IRB/REB Institutional Review Board or Research Ethics Board
Ng et al. Page 16
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
PROBE Prospective Database of Infants with Cholestasis
TB Total Bilirubin
Ng et al. Page 17
J Pediatr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
(online): Consort diagram describing ascertainment of sample with ND testing at Age 1 and 
Age 2.
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Figure 2. 
Distribution of Bayley scores at age one year (Age 1) and 2 years (Age 2) compared with the 
normal population. Chi-square test comparing distribution of scores in 3 bins with the 
normal population (≥100 [z score ≥0]; 85-99 [-1 ≤ z-score <0]; <85 [z< -1].
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Table 1
Participant demographic and clinical characteristics at Age 1 and Age 2.
Age 1 (N=132) Age 2 (N=85)
Demographics and medical history at baseline
 Gender – no. (%) 132 85
  Male 65(49.2%) 44 (51.8%)
  Female 67 (50.8%) 41 (48.2%)
 Race– no. (%) 126 84
  White 81 (64.3%) 61 (72.6%)
  Black 20 (15.9%) 10 (11.9%)
  Other 25 (19.8%) 13 (15.5%)
 Ethnicity– no. (%) 130 84
  Hispanic 23 (17.4%) 16 (19.0%)
  Non-Hispanic 107 (81.1%) 68 (81.0%)
 Highest household education– no. (%) 124 80
  Some high school or less 4 (3.0%) 1 (1.3%)
  High school diploma/GED 13 (10.5%) 11 (13.8%)
  Some college or more 107 (86.2%) 68 (85.0%)
 BASM syndrome– no. (%) 131 9 (6.9%) 85 5 (5.9%)
 Study group– no. (%) 132 85
  PROBE only 64 (48.5%) 39 (45.9%)
  Placebo in START trial 34 (25.8%) 18 (21.1%)
  Steroid in START trial 34 (25.8%) 28 (32.9%)
 Age at HPE (month) – mean (SD) 132 2.0 (0.9) 85 2.0 (0.7)
 Successful HPE*– no. (%) 120 91 (76.8%) 77 67 (87.0%)
Medical history in year prior to testing
 Ascites – no. (%) 132 38 (28.8%) 85 12 (14.1%)
 Cholangitis – no. (%) 132 68 (51.5%) 85 15 (17.7%)
 Spontaneous bacterial peritonitis– no. (%) 132 2 (1.5%) 85 4 (4.7%)
 Gastrointestinal bleeding– no. (%) 132 4 (3.0%) 85 4 (4.7%)
Measures taken at testing (+/- 2 mos.)
 Age at testing (month)– mean (SD) 132 12.4 (0.8) 85 24.2 (0.8)
 Growth parameters
  Weight Z-score– mean (SD) 128 -1.1 (1.3) 79 -0.1 (1.4)
  Height Z-score– mean (SD) 124 -0.9 (1.2) 78 -0.4 (1.1)
 Liver biochemical values
  Serum total bilirubin (mg/dl)– mean (SD) 126 2.2 (4.9) 76 1.3 (2.4)
  INR– mean (SD) 107 1.0 (0.2) 66 1.0 (0.1)
  Platelets (×109)–mean (SD) 112 223.4 (116.7) 70 214.1(106.2)
  Thrombocytopenia (i.e. platelet count <150)at testing 132 19 (14.4%) 85 14 (16.5%)
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aUnsuccessful HPE = never achieving a serum total bilirubin < 2 mg/dL within 3 months after HPE BASM=biliary atresia splenic malformation; 
HPE=hepatoportoenterostomy; INR=international normalized ratio.
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Table 3
Variables included in univariate and multivariate logistic regression results for “At Risk for Physical/Motor 
Delay”.
UNIVARIATE
Age 1 (N=132) Age 2 (N=85)
Odds Ratio (95% CI) P value Odds Ratio (95% CI) P value
Demographic variables
 Male vs. Female 0.84 (0.41, 1.73) 0.63 1.16 (0.43, 3.12) 0.76
 Race
  Black vs. White 0.34 (0.12, 0.95) 0.10 2.04 (0.49, 8.41) 0.30
  Other vs. White 0.62 (0.24, 1.61) 2.39 (0.70, 8.21)
 Non-Hispanic vs. Hispanic 0.37 (0.13, 1.06) 0.064 0.49(0.15, 1.62) 0.24
 Highest Household Education: College and above vs. High 
school or less 0.98 (0.35, 2.76) 0.98 0.45 (0.13, 1.54) 0.20
Baseline medical variables
 BASM syndrome NE n/a 4.31 (0.65, 28.66) 0.13
 Study Group
  START Steroid vs. START placebo 2.03 (0.69, 5.93) 0.20 0.75 (0.19, 2.99) 0.68
  START Steroid vs. PROBE only 0.86 (0.34, 2.22) 0.76 0.43 (0.13, 1.41) 0.17
  START Placebo vs. PROBE only 0.43 (0.17, 1.09) 0.076 0.67 (0.19, 2.34) 0.53
 Age at HPE 1.67 (1.05, 2.65) 0.030 1.56 (0.81, 2.99) 0.18
 Unsuccessful HPE (total bilirubin >2 at 3 mos.) 3.22 (1.19, 9.09) 0.022 0.21 (0.06, 0.76) 0.018
Medical variables since HPE
 Ascites 3.35 (1.35, 8.27) 0.009 1.99 (0.49, 8.12) 0.34
 Cholangitis 1.14 (0.55, 2.34) 0.73 2.55 (0.74, 8.79) 0.14
 Gastrointestinal bleeding 0.55 (0.03, 9.08) 0.67 2.93 (0.37, 23.16) 0.31
 Thrombocytopenia at testing (platelet <150 103/microliter) 2.09 (0.69, 6.34) 0.19 1.83 (0.52, 6.49) 0.35
 Combined medical risk** 2.59 (1.17, 5.73) 0.0187 2.95 (0.96, 9.03) 0.06
Variables on day of testing (+/- 2mos)
 Growth parameters
  Weight z-score 0.78 (0.59, 1.03) 0.080 0.93 (0.66, 1.32) 0.70
  Height z-score 0.68 (0.49, 0.95) 0.020 0.87 (0.54, 1.40) 0.57
 Liver biochemical values
  Serum total bilirubin (mg/dl) 1.09 (0.98, 1.21) 0.13 1.20 (0.96, 1.49) 0.11
  INR 2.70 (0.21, 35.21) 0.45 5.78 (0.14, 235.00) 0.35
MULTIVARIATE***
Age 1 (N=132) Age 2 (N=85)
Odds Ratio (95 % CI) P value Odds Ratio (95 % CI) P value
Height Z Score at Testing 0.70 (0.50, 0.98) 0.035 -- --
Ascites 3.17 (1.27, 7.93) 0.014 -- --
Unsuccessful HPE (TB > 2 ug/dL at 3 months) 4.88 (1.31, 16.7) 0.018
a
one or more of the following: History of ascites, or gastrointestinal bleed in preceding year; platelets <150 at time of testing.
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bStepwise selection process was used to arrive at final models. Only variables with p≤0.05 remain in the final models.
cOR >1.0 indicates increased risk for ND delay.
All models adjusted for Bayley version.
NE: not estimable; n/a: not applicable.
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Table 4
Variables included in univariate and multivariate logistic regression results for “At Risk for Mental/Cognitive/
Language Delay”.
UNIVARIATE
Age 1 (N=132) Age 2 (N=85)
Odds Ratio (95% CI) P value Odds Ratio (95% CI) P value
Demographics
 Male vs. Female 0.84 (0.41, 1.73) 0.63 0.99 (0.40, 2.46) 0.99
 Race 0.09 0.35
  Black vs. White 0.92 (0.34, 2.50) 3.45 (0.87, 13.77)
  Other vs. White 2.84 (1.09, 7.42) 3.12 (0.94, 10.33)
 Highest Household Education College and above vs. High 
school or less
1.55 (0.51, 4.73) 0.44 0.29 (0.09, 0.96) 0.043
Medical history at baseline
 BASM syndrome 3.64 (0.86, 15.34) 0.0784 7.51 (0.79, 71.10) 0.079
 Study Group
   START Steroid vs. START placebo 0.81 (0.30, 2.17) 0.67 2.28 (0.62, 8.41) 0.21
   START Steroid vs. PROBE only 1.01 (0.41, 2.50) 0.99 1.29 (0.48, 3.50) 0.62
   START Placebo vs. PROBE only 1.32 (0.54, 3.20) 0.54 0.65 (0.19, 2.25) 0.50
 Age at HPE 1.54 (1.02, 2.32) 0.038 1.86 (0.997, 3.46) 0.051
 Unsuccessful HPE (total bilirubin>2 at 3 mos) 2.13 (0.94, 5) 0.068 4.17 (1.12, 14.29) 0.0326
Medical history in year prior to testing
 Ascites 2.82 (1.28, 6.22) 0.010 3.80 (0.98, 14.81) 0.054
 Cholangitis 1.26 (0.62, 2.57) 0.53 0.61 (0.17, 2.16) 0.45
 Gastrointestinal bleeding NE n/a 1.76 (0.23, 13.33) 0.58
Thrombocytopenia at testing (platelet <150 103/microliter) 1.24 (0.46, 3.40) 0.67 1.94 (0.60, 6.28) 0.27
 Combined medical risk** 1.98 (0.95, 4.13) 0.068 2.98 (1.04, 8.56) 0.0420
Measures taken at testing (+/- 2 mos)
 Growth parameters
   Weight z-score 0.69 (0.52, 0.92) 0.012 0.96 (0.69, 1.34) 0.83
   Height z-score 0.66 (0.48, 0.92) 0.015 1.01 (0.66, 1.56) 0.95
 Liver biochemical values
   Serum total bilirubin (mg/dl) 1.11 (1.02, 1.21) 0.020 1.80 (1.17, 2.75) 0.0071
   INR 4.09 (0.49, 33.87) 0.19 1.72 (0.07, 57.21) 0.69
MULTIVARIATE
Age 1 (N=132) Age 2 (N=85)
Odds Ratio (95 % CI) P value Odds Ratio (95 % CI) P value
Race 0.010
  Black vs white 0.70 (0.22, 2.21)
  Other vs white 4.68 (1.56, 14.08)
Highest Household Education 0.26 (0.08, 0.90) 0.03
Weight z-score at testing 0.57 (0.41, 0.80) 0.0013 -- --
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UNIVARIATE
Age 1 (N=132) Age 2 (N=85)
Odds Ratio (95% CI) P value Odds Ratio (95% CI) P value
Ascites in last year 2.89 (1.23, 6.72) 0.014 -- --
Unsuccessful HPE (total bilirubin >2 at 3 mos) 4.76 (1.20, 16.67) 0.025
aOne or more of the following: History of ascites, or gastrointestinal bleed in preceding year; platelets<150 at time of testing.
bStepwise selection process was used to arrive at final models. Only variables with p≤0.05 remain in the final models.
cOR >1.0 indicates increased risk for ND delay.
All models adjusted for Bayley version.
NE: not estimable; n/a: not applicable
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